- Mar. Established a branch office in Singapore (Spectrum incubating, Golden Equator)
- Apr. Launched in Taiwan (Tseng Hsiang Life Science Ltd.)
Attracted investment from Korea Credit Guarantee Fund (Series A)
- Jun. Launched in Germany (PELOBIOTECH GmbH)
Launched in Singapore (Afirmus Biosource Pte. Ltd.)
Expanded the GMP-grade plant
- Sep. Selected for the small and medium enterprise technical innovation development project by the Ministry of SMEs and Startups
- Nov. Participated in the 2018 Qingdao Korea–China Technology Transfer Convention (Qingdao, China)
- Feb. Established a GMP-grade manufacturing plant
- Apr. Launched in Japan (Primetech)
- Feb. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (patent registered, China)
- May. Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells (patent registered, Korea)
- Jul. Attracted investment from Young Science Co., Ltd.
- Dec. Won the prime minister’s citation
- Mar. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (patent registered, Japan)
- Jun. Selected for the technology commercialization task by the Korea Institute of Marine Science & Technology Promotion
- Oct. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (patent registered, Japan)
Selected for the technology transfer and development project by Korea Technology & Information Promotion Agency for SMEs
- Mar. Launched the qPCR product
- Aug. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (2 patents registered, USA)
- Oct. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (Patent registered, USA)
- Jun. Launched DNA-free Taq DNA polymerase
- Aug. “Method for eliminating mycoplasma contamination of cells” (Patent registered, Korea)
- Oct. Selected for the start-up and growth tasks for the small and medium enterprises
- Jan. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (Patent registered, Korea)
- Apr. Acknowledged company-affiliated research institute (Korea Industrial Technology Association)
- Aug. Launched a diagnosis kit for the Mycoplasma qPCR
- Sep. Selected for a venture capital investment-related mentoring business
- Feb. Registered a BioMycoX trademark
- Apr. “Bone-transplant or a bone-filing composition comprising a dihydroxybenzoic acid derivative” (Patent pending, Europe)
- Aug. Launched the mycoplasma-related products in the United States
- Sep. Selected for the future marine industry technology development project in 2011 (support for marine small and medium venture businesses)
- Feb. Certified as a venture company (Korea Technology Finance Corporation)
- Mar. Selected as a G-startup project company in Gyeonggi Province
- Apr. Selected for a prestart-up support task in Gyeonggi Province
- Oct. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (Patent registered, Korea)
- Oct. Selected for residence in the business incubation center of Ajou University and started the business
-
Now ~ 2016
-
- Mar. Established a branch office in Singapore (Spectrum incubating, Golden Equator)
- Apr. Launched in Taiwan (Tseng Hsiang Life Science Ltd.)
Attracted investment from Korea Credit Guarantee Fund (Series A)
- Jun. Launched in Germany (PELOBIOTECH GmbH)
Launched in Singapore (Afirmus Biosource Pte. Ltd.)
Expanded the GMP-grade plant
- Sep. Selected for the small and medium enterprise technical innovation development project by the Ministry of SMEs and Startups
- Nov. Participated in the 2018 Qingdao Korea–China Technology Transfer Convention (Qingdao, China)
- Feb. Established a GMP-grade manufacturing plant
- Apr. Launched in Japan (Primetech)
- Feb. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (patent registered, China)
- May. Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells (patent registered, Korea)
- Jul. Attracted investment from Young Science Co., Ltd.
- Dec. Won the prime minister’s citation
-
2015 ~ 2011
-
- Mar. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (patent registered, Japan)
- Jun. Selected for the technology commercialization task by the Korea Institute of Marine Science & Technology Promotion
- Oct. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (patent registered, Japan)
Selected for the technology transfer and development project by Korea Technology & Information Promotion Agency for SMEs
- Mar. Launched the qPCR product
- Aug. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (2 patents registered, USA)
- Oct. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (Patent registered, USA)
- Jun. Launched DNA-free Taq DNA polymerase
- Aug. “Method for eliminating mycoplasma contamination of cells” (Patent registered, Korea)
- Oct. Selected for the start-up and growth tasks for the small and medium enterprises
- Jan. “Bone transplant or a bone-filling composition comprising a dihydroxybenzoic acid derivative” (Patent registered, Korea)
- Apr. Acknowledged company-affiliated research institute (Korea Industrial Technology Association)
- Aug. Launched a diagnosis kit for the Mycoplasma qPCR
- Sep. Selected for a venture capital investment-related mentoring business
- Feb. Registered a BioMycoX trademark
- Apr. “Bone-transplant or a bone-filing composition comprising a dihydroxybenzoic acid derivative” (Patent pending, Europe)
- Aug. Launched the mycoplasma-related products in the United States
- Sep. Selected for the future marine industry technology development project in 2011 (support for marine small and medium venture businesses)
-
2010 ~ 2009
-
- Feb. Certified as a venture company (Korea Technology Finance Corporation)
- Mar. Selected as a G-startup project company in Gyeonggi Province
- Apr. Selected for a prestart-up support task in Gyeonggi Province
- Oct. “Method for culturing mycoplasma contamination-free cells and method for removing mycoplasma contamination of cells” (Patent registered, Korea)
- Oct. Selected for residence in the business incubation center of Ajou University and started the business